

Giovanni Tarantino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1317457/publications.pdf>

Version: 2024-02-01

133
papers

4,820
citations

71061

41
h-index

110317

64
g-index

137
all docs

137
docs citations

137
times ranked

7046
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World Journal of Gastroenterology, 2010, 16, 4773.	1.4	166
2	What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?. World Journal of Gastroenterology, 2013, 19, 802.	1.4	164
3	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. European Journal of Gastroenterology and Hepatology, 2009, 21, 504-511.	0.8	161
4	Non-alcoholic fatty liver disease: Further expression of the metabolic syndrome. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 293-303.	1.4	147
5	What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. World Journal of Gastroenterology, 2013, 19, 3375.	1.4	147
6	A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatology Research, 2007, 37, 410-415.	1.8	139
7	Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 5839.	1.4	137
8	Drug-induced liver injury: Is it somehow foreseeable?. World Journal of Gastroenterology, 2009, 15, 2817.	1.4	114
9	Liver-spleen axis: Intersection between immunity, infections and metabolism. World Journal of Gastroenterology, 2013, 19, 3534.	1.4	113
10	JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World Journal of Gastroenterology, 2011, 17, 3785.	1.4	113
11	Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy. Journal of Clinical Medicine, 2020, 9, 15.	1.0	111
12	Spleen: A new role for an old player?. World Journal of Gastroenterology, 2011, 17, 3776.	1.4	104
13	Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiology, 2015, 10, 889-902.	1.0	100
14	Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. Journal of Translational Medicine, 2015, 13, 169.	1.8	97
15	Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study. Journal of Clinical Medicine, 2021, 10, 346.	1.0	94
16	Should visceral fat be reduced to increase longevity?. Ageing Research Reviews, 2013, 12, 996-1004.	5.0	88
17	What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?. BMC Gastroenterology, 2009, 9, 89.	0.8	85
18	Inhibition of the mTOR pathway: A possible protective role in coronary artery disease. Annals of Medicine, 2013, 45, 348-356.	1.5	85

#	ARTICLE	IF	CITATIONS
19	Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. <i>BMC Gastroenterology</i> , 2009, 9, 21.	0.8	83
20	Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. <i>Clinical Endocrinology</i> , 2013, 78, 447-453.	1.2	79
21	Is serum Interleukin-17 associated with early atherosclerosis in obese patients?. <i>Journal of Translational Medicine</i> , 2014, 12, 214.	1.8	75
22	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 3141-3158.	5.4	74
23	Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?. <i>Journal of Translational Medicine</i> , 2008, 6, 72.	1.8	72
24	Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or Slightly Increased Liver Enzymes. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-10.	1.9	65
25	Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively?. <i>Journal of Inflammation</i> , 2009, 6, 6.	1.5	64
26	Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 5280.	1.4	63
27	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. <i>Journal of Translational Medicine</i> , 2015, 13, 303.	1.8	63
28	Pathogenesis of hepatic steatosis: The link between hypercortisolism and non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 6735.	1.4	62
29	Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2012, 18, 6790.	1.4	61
30	It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13424.	1.8	61
31	Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2014, 20, 9217-28.	1.4	59
32	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. <i>World Journal of Gastroenterology</i> , 2010, 16, 6119.	1.4	57
33	Could SCGF-Beta Levels Be Associated with Inflammation Markers and Insulin Resistance in Male Patients Suffering from Obesity-Related NAFLD?. <i>Diagnostics</i> , 2020, 10, 395.	1.3	56
34	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. <i>Journal of Translational Medicine</i> , 2011, 9, 136.	1.8	53
35	Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1266-1268.	1.4	51
36	Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase?. <i>Journal of Translational Medicine</i> , 2012, 10, 50.	1.8	49

#	ARTICLE	IF	CITATIONS
37	Drug-induced liver injury due to "natural products" used for weight loss: A case report. <i>World Journal of Gastroenterology</i> , 2009, 15, 2414.	1.4	48
38	Exposure to ambient air particulate matter and non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 3951.	1.4	48
39	Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-14.	1.9	48
40	Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. <i>World Journal of Gastroenterology</i> , 2015, 21, 6892-6897.	1.4	47
41	Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2007, 37, 48-53.	1.7	42
42	Should nonalcoholic fatty liver disease be regarded as a hepatic illness only?. <i>World Journal of Gastroenterology</i> , 2007, 13, 4669.	1.4	42
43	Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 121-124.	0.7	41
44	Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailability. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1511-1517.	1.4	41
45	Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. <i>Thrombosis Research</i> , 2011, 127, 193-197.	0.8	38
46	Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-Blockers. <i>Journal of Rheumatology</i> , 2012, 39, 1042-1046.	1.0	38
47	Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?. <i>World Journal of Gastroenterology</i> , 2014, 20, 16649.	1.4	38
48	Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3948.	1.8	36
49	Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2012, 21, 293-302.	0.5	35
50	Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2011, 25, 47-56.	0.7	33
51	Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. <i>Nutrition and Metabolism</i> , 2011, 8, 84.	1.3	32
52	A Pharmacokinetic Interaction Between Clarithromycin and Sirolimus in Kidney Transplant Recipient. <i>Current Drug Metabolism</i> , 2007, 8, 379-381.	0.7	30
53	ECMPs permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side effects. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 617-624.	1.0	30
54	Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-blockers treatment: a prospective study. <i>Arthritis Research and Therapy</i> , 2012, 14, R211.	1.6	30

#	ARTICLE	IF	CITATIONS
55	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. <i>Growth Hormone and IGF Research</i> , 2015, 25, 28-33.	0.5	30
56	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2013, 19, 5402.	1.4	29
57	Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. <i>Internal and Emergency Medicine</i> , 2009, 4, 315-323.	1.0	26
58	Carotid Intima-Media Thickness Is Predicted by Combined Eotaxin Levels and Severity of Hepatic Steatosis at Ultrasonography in Obese Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e105610.	1.1	26
59	Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 359-368.	0.5	26
60	Evaluation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3019-3025.	0.4	25
61	Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. <i>Clinical and Investigative Medicine</i> , 2008, 31, 24.	0.3	25
62	Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors. <i>Current Drug Metabolism</i> , 2011, 12, 253-267.	0.7	24
63	Hepatitis C virus lymphotropism and peculiar immunological phenotype: Effects on natural history and antiviral therapy. <i>World Journal of Gastroenterology</i> , 2009, 15, 2305.	1.4	24
64	A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. <i>Diagnostics</i> , 2022, 12, 431.	1.3	23
65	Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 605-612.	0.8	20
66	Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study. <i>Future Science OA</i> , 2021, 7, FSO643.	0.9	20
67	The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. <i>Clinical and Investigative Medicine</i> , 2007, 30, 192.	0.3	20
68	Mammalian Target of Rapamycin in Inflammatory Skin Conditions. <i>European Journal of Inflammation</i> , 2014, 12, 341-350.	0.2	18
69	Gut Microbiome, Obesity-Related Comorbidities, and Low-Grade Chronic Inflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2343-2346.	1.8	18
70	Extensive psoriasis induced by pegylated interferon: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 86.	0.4	17
71	Interferon-alpha 2 but not Interferon-gamma serum levels are associated with intramuscular fat in obese patients with nonalcoholic fatty liver disease. <i>Journal of Translational Medicine</i> , 2019, 17, 8.	1.8	16
72	Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients. <i>Frontiers in Medicine</i> , 2021, 8, 634962.	1.2	16

#	ARTICLE	IF	CITATIONS
73	Non-alcoholic fatty liver disease, diet and gut microbiota. EXCLI Journal, 2014, 13, 461-90.	0.5	16
74	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. Critical Reviews in Environmental Science and Technology, 2013, 43, 1223-1245.	6.6	15
75	Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?. Hepatology International, 2013, 7, 413-428.	1.9	14
76	Liver-spleen axis in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2021, 15, 759-769.	1.4	14
77	Is visceral fat reduction necessary to favour metabolic changes in the liver?. Journal of Gastrointestinal and Liver Diseases, 2012, 21, 205-8.	0.5	14
78	Recreational Drugs: a New Health Hazard for Patients with Concomitant Chronic Liver Diseases. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 79-84.	0.5	13
79	Hepatic steatosis in overweight/obese females: Newscreening method for those at risk. World Journal of Gastroenterology, 2009, 15, 5693.	1.4	13
80	Similar Serum Levels of IL-6 and its Soluble Receptors in Patients with HCV-Related Arthritis and Rheumatoid Arthritis: A Pilot Study. International Journal of Immunopathology and Pharmacology, 2012, 25, 281-285.	1.0	12
81	Could quantitative liver function tests gain wide acceptance among hepatologists?. World Journal of Gastroenterology, 2009, 15, 3457.	1.4	12
82	Does Spleen Volume Play a Role in Patients with HCV-Related Chronic Hepatitis?. International Journal of Immunopathology and Pharmacology, 2009, 22, 1009-1017.	1.0	11
83	Long-Term Assessment of Plasma Lipids in Transplant Recipients Treated with Tacrolimus in Relation to Fatty Liver. International Journal of Immunopathology and Pharmacology, 2010, 23, 1303-1308.	1.0	11
84	Urinary Excretion of 5-Hydroxy-3-Indoleacetic Acid in Dystimic/Depressed, Adult Obese Women: What Correlations to Hepatic Steatosis?. International Journal of Immunopathology and Pharmacology, 2011, 24, 769-779.	1.0	11
85	Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?. Journal of Clinical Medicine, 2019, 8, 1510.	1.0	11
86	PaO ₂ /FiO ₂ ratio forecasts COVID-19 patients'™ outcome regardless of age: a cross-sectional, monocentric study. Internal and Emergency Medicine, 2022, 17, 665-673.	1.0	11
87	Can Serum TGF-BETA 1 Be Used to Evaluate the Response to Antiviral Therapy of Haemophilic Patients with HCV-Related Chronic Hepatitis ?. International Journal of Immunopathology and Pharmacology, 2008, 21, 1007-1012.	1.0	10
88	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. Critical Reviews in Environmental Science and Technology, 2013, 43, 752-774.	6.6	10
89	Hematocrit Values Predict Carotid Intimal-Media Thickness in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. Frontiers in Endocrinology, 2018, 9, 203.	1.5	10
90	Oleuropein overrides liver damage in steatotic mice. Journal of Functional Foods, 2020, 65, 103756.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?. <i>Viruses</i> , 2021, 13, 1285.	1.5	9
92	Non-alcoholic fatty liver disease, obesity and other illnesses. <i>Clinical and Investigative Medicine</i> , 2008, 31, 290.	0.3	9
93	Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. <i>Liver International</i> , 2003, 23, 413-419.	1.9	8
94	Absence of Pharmacokinetic Interference of Moxifloxacin on Cyclosporine and Tacrolimus in Kidney Transplant Recipients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 576-580.	1.0	8
95	Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver staging. <i>Ultrasound in Medicine and Biology</i> , 2004, 30, 599-604.	0.7	7
96	Insulin-like Growth Factor-1, Psoriasis, and Inflammation: A MÃ©nage Å Trois?. <i>European Journal of Inflammation</i> , 2011, 9, 277-283.	0.2	7
97	Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. <i>European Journal of Clinical Investigation</i> , 2016, 46, 651-657.	1.7	7
98	Do Transferrin Levels Predict Haemodialysis Adequacy in Patients with End-Stage Renal Disease?. <i>Nutrients</i> , 2019, 11, 1123.	1.7	7
99	Gastrointestinal peptides and nonalcoholic fatty liver disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 11-15.	1.2	7
100	HCV infection and chronic arthritis: Does viral replication matter?. <i>Hepatology Research</i> , 2006, 35, 238-241.	1.8	6
101	Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?. <i>Hepatitis Monthly</i> , 2013, 13, e7560.	0.1	6
102	Troponin Levels Relate to CRP Concentrations in Patients With NAFLD on Maintenance Haemodialysis: A Retrospective Study. <i>Advances in Therapy</i> , 2020, 37, 3337-3347.	1.3	6
103	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 267-79.	1.8	6
104	Nesfatin-1: role as possible new anti-obesity treatment. <i>EXCLI Journal</i> , 2014, 13, 586-91.	0.5	6
105	â€œObesity paradoxâ€•or â€œmetabolically benign obesityâ€?. <i>Eating and Weight Disorders</i> , 2013, 18, 337-338.	1.2	5
106	Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C (and Congenital) Tj ETQq0 0 0 rBT /Overlock 10 Tf 50 142	1.5	5
107	Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with â€œExplosiveâ€•Immune Response in Course of HCV-Related Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 14075-14085.	1.8	5
108	New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. <i>Advances in Therapy</i> , 2021, 38, 2094-2113.	1.3	5

#	ARTICLE	IF	CITATIONS
109	What Non-Alcoholic Fatty Liver Disease Has Got to Do with Obstructive Sleep Apnoea Syndrome and viceversa?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 291-299.	0.5	5
110	Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis?. <i>World Journal of Gastroenterology</i> , 2011, 17, 1606.	1.4	5
111	Exaggerated Immune Reactions Predict the Outcome of Interferon Therapy in Patients with Chronic Hepatitis C. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 837-840.	1.0	4
112	Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?. <i>Journal of Viral Hepatitis</i> , 2008, 15, 646-650.	1.0	4
113	Circulating Levels of Interferon- β in Course of Hepatitis C Virus-Related Arthritis. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 389-392.	0.5	4
114	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. <i>European Journal of Inflammation</i> , 2013, 11, 179-191.	0.2	4
115	Lipids Nutrition and Epigenetic Modification in Obesity-Related Co-Morbidities * *All authors equally contributed to draft the manuscript. All authors gave final approval of the version to be published. Disclosure statement: The authors declare that there are no conflicts of interest.. , 2016, , 85-110.		4
116	Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study. <i>In Vivo</i> , 2017, 31, 709-712.	0.6	4
117	Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12947.	1.8	4
118	Nutrition: a promising route for prevention and management of obesity-related nonalcoholic fatty liver disease. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2014, 20, 39-41.	0.3	3
119	Serum levels of Lp(a) are related to waist circumference in NAFLD patients with low prevalence of co-morbidities. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 544-552.	0.6	3
120	Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 928-935.	0.7	3
121	Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?. <i>World Journal of Gastroenterology</i> , 2007, 13, 4903.	1.4	3
122	Could high levels of tissue polypeptide specific antigen, a marker of apoptosis detected in nonalcoholic steatohepatitis, improve after weight loss?. <i>Disease Markers</i> , 2009, 26, 55-63.	0.6	3
123	NAFLD or MAFLD: That is the conundrum. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 103-103.	0.6	3
124	Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage. <i>Nutrition and Metabolism</i> , 2022, 19, 9.	1.3	3
125	Hepatitis C Virus-Related Arthritis and Rheumatoid Arthritis: Could They Be Different Aspects of the Same Disease?. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 293-296.	1.0	2
126	Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: A cross-sectional retrospective study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 68, 126802.	1.5	2

#	ARTICLE	IF	CITATIONS
127	From bed to bench: Which attitude towards the laboratory liver tests should health care practitioners strike?. World Journal of Gastroenterology, 2007, 13, 4917.	1.4	2
128	Synchronous Onset of Secondary Raynaud's Phenomenon in Monozygotic Twins. European Journal of Inflammation, 2012, 10, 535-537.	0.2	1
129	Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 275-280.	0.6	1
130	Lipids, Low-Grade Chronic Inflammation and NAFLD. , 2016, , 731-759.		1
131	Beyond Nutrition Is There Any Role for Physical Activity in Nonalcoholic Fatty Liver Disease Therapy?. , 2014, , 79-87.		0
132	Suggestive hypothesis on a case report: Patient presenting with cyclical ovarian cysts coupled to increased cholestatic enzymes. Journal of Obstetrics and Gynaecology Research, 2019, 45, 477-481.	0.6	0
133	Sleep Quality Associated with the Onset of NAFLD: Suggested Hypotheses. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 143-144.	0.5	0